Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT00072943
  4. Details
NCT00072943 Clinical Trial

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Crohn's Disease Clinical Trial

Official title:
A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00072943
Other study ID # 707
Secondary ID
Status Completed
Phase Phase 2
First received November 12, 2003
Last updated March 9, 2012
Start date March 2002
Est. completion date April 2004

Study information
Verified date March 2012
Source Facet Biotech
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD). HuZAF is a humanized anti-Interferon-gamma (anti-IFN-γ) monoclonal antibody, which binds and blocks IFN-γ, a protein in the immune system that is involved in inflammation. Antibodies are proteins normally produced by our immune system to help fight off foreign substances. Scientists have been able to make therapeutic humanized monoclonal antibodies, similar to the antibodies in our bodies, to target diseases.

Description:

Participants will be randomized, assigned by chance, to one of five treatment groups consisting of: four groups differing in the amount of study drug given and one placebo group. The initial dose of study drug will be given intravenously, injected into a vein in the arm. Four weeks later, three subsequent doses of study drug will be given subcutaneously, through the skin, every four weeks for three doses. Patients will be followed for approximately six months after receiving their final dose.

Recruitment information / eligibility
Status Completed
Enrollment 175
Est. completion date April 2004
Est. primary completion date April 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility - Patients 18-70 years old

- Patients with moderate to severe Crohn's disease

- Patients who have had Crohn's disease for at least 6 months

- Patients who have previously been treated for Crohn's disease

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• anti-Interferon-gamma monoclonal antibody

Locations
Country Name City State
Canada Queen Elizabeth II Health Science Center, McKenzie Building, Pathology Halifax, Nova Scotia
Canada London Health Science Center, University Campus London, Ontario
Canada Vancouver General Hospital, Dept. of Medicine Vancouver British Columbia
Canada Health Science Centre Winnipeg Manitoba
United States Advanced Clinical Research Institute Anaheim California
United States Atlanta Gastroenterology Associates Atlanta Georgia
United States Massachusetts General Hospital, Gastrointestinal Unit Boston Massachusetts
United States Carolina Digestion Health Associates Charlottesville North Carolina
United States University of Virginia Health System Charlottesville Virginia
United States Doctor's Office Chicago Illinois
United States Consultants for Clinical Research Cincinnati Ohio
United States The Cleveland Clinic Foundation Cleveland Ohio
United States Gainesville VA Medical Center Gainesville Florida
United States Houston Medical Research Associates Houston Texas
United States University of Kentucky Medical Center, Division of Digestive Disease & Nutrition Lexington Kentucky
United States Gastroenterology Specialities P.C. Lincoln Nebraska
United States Doctor's Office Orange California
United States University Pittsburgh Medical Center, Division of Gastroenterology, Hepatology and Nutrition, Inflammatory Bowel Disease Center Pittsburgh Pennsylvania
United States Waterside Clinical Research Services, Inc. West Palm Beach Florida

Sponsors (1)
Lead Sponsor Collaborator
Facet Biotech

Countries where clinical trial is conducted

United States,  Canada, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01951326 - Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Phase 3

External Links